Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001127602-12-025539
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-08-31 18:00:10
Reporting Period:
2012-08-30
Filing Date:
2012-08-31
Accepted Time:
2012-08-31 18:00:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
318154 Amgen Inc AMGN Biological Products, (No Disgnostic Substances) (2836) 953540776
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1016369 D Leonard Schaeffer One Amgen Center Drive
Thousand Oaks CA 91320-1799
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-08-30 5,000 $74.89 21,316 No 4 M Direct
Common Stock Disposition 2012-08-30 5,000 $83.25 16,316 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Nqso (Right to Buy) Disposition 2012-08-30 5,000 $0.00 5,000 $74.89
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2006-03-15 2013-03-15 No 4 M Direct
Footnotes
  1. The price reported is an average price. The prices ranged from $83.23 to $83.26 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer.
  2. These shares include 61 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's unvested, and vested but deferred, Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.